According to the companies, the agreement will open a channel between federal health facilities and CorneaGen's laboratories.
MellingMedical and CorneaGen today announced an agreement that will expand corneal tissue options for doctors in the federal health system, including the Veterans Health Administration.
"More than 250,000 American veterans currently receive disability compensation for eye or vision conditions," Chris Melling, founder and CEO of MellingMedical noted in the statement, "We're honored to work with CorneaGen to increase the quantity and quality of corneal tissue available for treating veterans potentially suffering from sight loss or impairment due to glaucoma."
According to a news release from the companies, the agreement will open a channel between federal health facilities and CorneaGen's laboratories whose advanced tissue processing methods yield more corneas than any other corneal tissue organization in the U.S. The Seattle-based company's comprehensive portfolio of corneal transplant tissue is processed to the standards set by the FDA and the Eye Bank Association of America.
"CorneaGen provides the highest quality donor tissue, service, and products to surgeons and their patients while driving innovations in corneal care," Bernie Iliakis, president of CorneaGen said in the statement. "This partnership with MellingMedical expands our commitment to transforming the lives of those impacted by corneal disease by restoring sight, especially America's veterans."